Outcome Research to Confirm the Anti-anginal Effect of T89 in Patients With Stable Angina

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 765 participants.

Also called NCT03789552

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 765 participants (planned count) (from the registry)
Sponsor
Tasly Pharmaceuticals, Inc. (from the registry)
Registry
  • NCT NCT03789552
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT03789552. Randomized; quadruple masking; primary purpose treatment. Start 2019-08-01 (actual); primary completion 2026-12 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Outcome Research to Confirm the Anti-anginal Effect of T89 in Patients With Stable Angina
Condition
Chronic Stable Angina Pectoris
Intervention (Drug)
T89 capsule
Intervention (Drug)
Placebo capsule
Lead sponsor
Tasly Pharmaceuticals, Inc. (class: industry)

Record details

Record id
cardio:ct-nct03789552
Content hash
ed400b919044b5576b1ea3ebb336b4476dca5ecb82ee81655c710e1ce5cc3a90